πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 650 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 8211915

Biphenyl compounds useful as muscarinic receptor antagonists

Theravance, Inc. Β· Granted Tue Jul 03 2012 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 28 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8211894

Heteroarylalkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists

Theravance, Inc. Β· Granted Tue Jul 03 2012 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 28 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8207170

Heterocyclic substituted piperazines with CXCR3 antagonist activity

Pharmacopeia Drug Discovery, Inc. Β· Granted Tue Jun 26 2012 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 21 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8202891

Quaternary ammonium compounds useful as muscarinic receptor antagonists

Theravance, Inc. Β· Granted Tue Jun 19 2012 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 14 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8198304

Guanidine-containing compounds useful as muscarinic receptor antagonists

Theravance, Inc. Β· Granted Tue Jun 12 2012 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 07 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8173815

Biphenyl compounds useful as muscarinic receptor antagonists

Theravance, Inc. Β· Granted Tue May 08 2012 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 03 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8168678

N,N-disubstituted aminoalkylbiphenyl antagonists of prostaglandin D2 receptors

Panmira Pharmaceuticals, LLC Β· Granted Tue May 01 2012 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 26 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8163737

CGRP receptor antagonists

Vertex Pharmaceuticals Incorporated Β· Granted Tue Apr 24 2012 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 19 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8163805

Small molecule antagonists of Bcl-2 family proteins

THE REGENTS OF THE UNIVERSITY OF MICHIGAN Β· Granted Tue Apr 24 2012 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 19 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8153781

Dendrimer conjugates of agonists and antagonists of the GPCR superfamily

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Apr 10 2012 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 05 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8153686

Amino- and amido-aminotetralin derivatives and related compounds as mu opioid receptor ant

Theravance, Inc. Β· Granted Tue Apr 10 2012 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 05 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8143277

Method of using compounds having Ξ²2 adrenergic receptor agonist and muscarinic receptor an

Theravance, Inc. Β· Granted Tue Mar 27 2012 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 22 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8143226

Tyrosine kinase receptor antagonists and methods of treatment for breast cancer

The Regents of the University of California Β· Granted Tue Mar 27 2012 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 22 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8138345

Diamide compounds having muscarinic receptor antagonist and Ξ²2 adrenergic receptor agonist

Theravance, Inc. Β· Granted Tue Mar 20 2012 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 15 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8138216

Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders,

Jenrin Discovery, LLC Β· Granted Tue Mar 20 2012 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 15 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8133905

Biphenyl compounds useful as muscarinic receptor antagonists

Theravance, Inc. Β· Granted Tue Mar 13 2012 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 08 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8133904

Cannabinoid receptor antagonists/inverse agonists useful for treating obesity

Jenrin Discovery, LLC Β· Granted Tue Mar 13 2012 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 08 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8134006

Dialkylphenyl compounds having Ξ²2 adrenergic receptor agonist and muscarinic receptor anta

Theravance, Inc. Β· Granted Tue Mar 13 2012 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 08 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8124627

Biphenyl compounds useful as muscarinic receptor antagonists

Theravance, Inc. Β· Granted Tue Feb 28 2012 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 23 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8119796

Biphenyl compounds useful as muscarinic receptor antagonists

Theravance, Inc. Β· Granted Tue Feb 21 2012 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 16 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8114394

Use of IL-1 antagonists to treat gout

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Feb 14 2012 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 09 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8110546

VEGF antagonist formulations

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Feb 07 2012 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 02 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8106232

3-carboxypropyl-aminotetralin derivatives and related compounds as mu opioid receptor anta

Theravance, Inc. Β· Granted Tue Jan 31 2012 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 26 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8101791

Aminotetralin compounds as mu opioid receptor antagonists

Theravance, Inc. Β· Granted Tue Jan 24 2012 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 19 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted